key: cord-0758088-ha3zxzp3 authors: Pilmis, B; Elkaibi, I; Péan de Ponfilly, G; Daikha, H; Bouzid, A; Guihot, A; Castreau, N; Pradere, P; Ketatni, H; Mondragon, A; Hayem, G; Le Pavec, J; Laplanche, S; Le Monnier, A title: Evolution of anti-SARS-CoV-2 immune response in a cohort of French healthcare workers followed for 7 months date: 2022-01-19 journal: Infect Dis Now DOI: 10.1016/j.idnow.2022.01.004 sha: a4e784dcd7a476991f7c74138a8975f58f7d64ee doc_id: 758088 cord_uid: ha3zxzp3 Objectives. We aimed to understand the immune response among healthcare workers (HCWs) following SARS-CoV-2 infection, and to determine the infection prevalence during the first wave of the pandemic among workers in our hospital. Methods. Determination of the serological status against SARS-CoV-2 (nucleocapsid) was offered to all HCWs. All HCWs with positive SARS-CoV-2 serology were proposed to be included in a longitudinal medical and serological follow-up (anti-spike) for 7 months. Results. We included 3,062 HCWs; 256 (8.4%) were positive for anti-SARS-CoV-2 nucleocapsid IgG. Among them, early decrease in the anti-nucleocapsid antibody index was observed between the first (S1) and second (S2) serology samplings in 208 HCWs (84.2%). The initial anti-nucleocapsid IgG index seemed to be related to the HCWs’ age. Seventy-four HCWs were included in the 7-month cohort study. Among them, 69 (90.5%) had detectable anti-spike IgG after 7 months and 24 (32.4%) reported persistent symptoms consistent with post-acute COVID-19 syndrome diagnosis. Conclusion. The prevalence of serological positivity among HCWs was 6.7%. Infection should be followed by vaccination because of antibody decrease. Coronavirus disease 2019 , caused by the human pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a severe disease that has resulted in widespread morbidity and mortality worldwide. Healthcare workers (HCWs) are at high risk of infection due to close contact with SARS-CoV-2-infected patients [2] . Studies of active and past infections, defined as the presence of SARS-CoV-2 immunoglobulin G (IgG) antibodies, reported that the risk for HCWs comes from work-related exposure (patients and coworkers), as well as from the communities in which they live [3] . Prompt identification of cases by realtime reverse-transcriptase polymerase chain reaction (RT-PCR) screening at hospitals is crucial to avoid new infections and implementation of isolation and quarantine measures of HCWs [4] . Previous studies conducted among HCWs found a cumulative prevalence of SARS-CoV-2 infections ranging from 11% to ˃40% [5, 6] . Prevalence varies according to the timing within the pandemic, location, country, and type of HCWs. The presence of IgG indicates recent or past contact with SARS-CoV-2. Measurable IgG for SARS-CoV-2 antigens develop after most, but not all, SARS-CoV-2 infections [3, [7] [8] [9] . Serological responses against SARS-CoV-2 are usually detectable within 1 to 3 weeks after disease onset [10, 11] . SARS-CoV-2 IgG titers change over time [12] . The spike (S) protein and nucleocapsid (N) are the major coronavirus antigens that induce immunoglobulin (Ig) production [13] . Antibodies against the N protein, which are the main target for serological diagnosis, are often induced at a relatively higher level than others [13, 14] . We established the Saint-Joseph Hospital Healthcare Worker SARS-CoV-2 Serology Cohort Study in April-May 2020 to understand the immune response following SARS-CoV-2 infection and to determine the infection prevalence following the first wave of the pandemic among workers in our hospital. The study was conducted at the Paris Saint Joseph Hospital Group from April to November 2020. Paris Saint Joseph hospital is a 894-bed tertiary-care teaching hospital, located in Paris and sub-area, France, and employing 3,612 HCWs. Determination of the serological status against SARS-CoV-2 (Np) (twice, with a 30-day interval between the first (S1) and second sample (S2)) was proposed to all HCWs. The invitation targeted physicians, nurses, hospital assistants, and hospital administrative staff. Following informed consent, participants completed a questionnaire that covered sociodemographic information and details related to SARS-CoV-2 infection, including the date of PCR testing, date of symptom onset, and a description of symptoms (ageusia, anosmia, asthenia, dry cough, diarrhea, fever, headache, chest pain, myalgia, shivers) (1-month cohort study). All HCWs with positive SARS-CoV-2 serology were proposed to be included in a longitudinal medical and serological follow-up (day 90 (S3) -day 210 (S4)) ( Figure 1 , 7-month cohort study). Post-acute COVID-19 syndrome was defined as the persistence of symptoms and organ damage that stretched beyond the 3-month period after the infection [15] . Anti-SARS-CoV-2 IgG in serum samples was measured using the Abbott Architect i2000 which is calculated by the system as an Index (S/C) for the semi-quantitative test or converted to AU/ml for the quantitative test. Antibody index ≥1.40 arbitrary units of the manufacturer were considered positive for anti-SARS-CoV-2 nucleocapsid IgG; those between 0.49-1.39 were considered equivocal (following Abbott Diagnostics Product Information Letter PI1060-2020); and those <0.49 were considered negative. The positivity threshold for anti-SARS-CoV-2 spike-1 IgG was 50 AU/ml. The ELISpot IFN-γ assay is a reference method to explore T-cell response. ELISpot IFN-γ assays were performed on PBMCs and BAL-collected cells, as previously described [16] , using ELISpot IFN-γ-pair-antibodies (Diaclone). Briefly, 1 x 10 5 PBMCs/well were plated (Merck Millipore, Molsheim, France) in triplicate with medium, phytohemagglutinin (2 µg/mL, Sigma-Aldrich) or SARS-CoV-2-peptide pools (2 µg/mL). Plates were developed with streptavidin-alkaline phosphatase conjugate (Amersham, Freiburg, Germany) and NBT/BCIP substrate (Sigma-Aldrich) and then air-dried for 24 hours before spot-forming cell units (SFC) were read (AID Elispot reader, Autoimmun Diagnostika GmbH, Straßberg, Germany). Results are expressed as the mean SFC x 10 6 from triplicates after background subtraction. The positivity threshold was set at 50 SFC/10 6 PBMCs. SARS-CoV-2 overlapping 18-mer-peptides covering the viral nucleocapsid and spike proteins were tested separately. HCW characteristics are presented using means ± standard deviation (SD), medians [interquartile range], and percentages for categorical variables. Percentages were calculated based on documented data (missing data were excluded from percentages). Inter-group comparisons were made using the Mann-Whitney test for quantitative variables and Fisher's exact test for qualitative variables. The statistical analysis was performed using the R software (version 3.2.2). All tests were two-tailed and p values <0.05 (calculated by chi-2 test, Student's t test, or Mann-Whitney test) were considered significant. The trial obtained approval from the independent Ethics Committee "Sud Méditérrannée I" on May 5,2020 (2020-A01837-32) and was conducted according to Good Clinical Practices and the Declaration of Helsinki, as last amended. The study was sponsored by the Paris Saint-Joseph Hospital Group. Among the 3,612 HCWs in the hospital group, 3,062 (85%) agreed to participate and were included in the 1-month cohort. After the first two serological tests (S1 and S2), 256 (8.4%) HCWs were positive for anti-SARS-CoV-2 nucleocapsid IgG. This included symptomatic as well as asymptomatic HCWs, and all were asked to participate in the 7-month cohort study. Among the 256 included HCWs, the mean age was 38.2  11.9 years, with a sex ratio (M/F) of 0.3. Among them, 116 (45.3%) had RT-PCR performed, of whom 81 (69.8%) had a positive result. Average time between RT-PCR and serology was 31 days. In total, 247 (96.5%) HCWs were positive to the first serological test (S1) for anti-nucleocapsid IgG, of whom 72 (29.1%) reported a history of positive SARS-CoV-2 RT-PCR. After the second serology (S2), nine additional HCWs were detected positive following late infection at the end of the first epidemic wave. Thanks to S2, we observed an early decrease in the anti-nucleocapsid antibody index between the first (S1) and second (S2) serologies for 208 (84.2%) HCWs, which led to offering a longitudinal follow-up to all these HCWs. We analyzed the evolution of the anti-nucleocapsid IgG index. There were no factors associated with the increase or decrease of the anti-nucleocapsid IgG index (age, sex, SARS-CoV-2-related infection). However, the initial antibody index seemed to be related to the HCWs' age ( Figure 2 ). For HCWs ≤40 years of age, the median antibody index was 4.52 [2.95-6.48], whereas it was 6.4 [4] [5] [6] [7] [8] for HCWs >40 years of age (p<0.01 in multivariate analysis), irrespective of disease severity. Overall, 74 HCWs (28.9%) agreed to participate in the longitudinal medical and serological study over a period of 7 months and provided ≥2 samples for serological testing. HCW characteristics are summarized in Table 1 However, prior symptoms compatible with COVID-19 and a positive SARS-CoV-2 RT-PCR were not associated with persistence of a positive serological test at day 90. There was no difference in the anti-nucleocapsid antibody index at S1, S2, S3, or S4 between HCWs with post COVID-19 syndrome and those with no persistent symptom. The observed anti-nucleocapsid IgG antibody evolution is presented in Figure 3A . Among the 74 included HCWs, 69 (90.5%) had detectable anti-spike IgG at S4. Of the five (6.7%) for whom serology was negative, four never had positive anti-spike IgG titer and the last was negative as early as S1. Despite a significant reduction between S1 and S2, anti-spike IgG titers remained above the positive threshold for most seropositive HCWs for the duration of the study (up to 210 days, Figure 3B (Table 2 ). There was no statistical association between response and age or presence of symptoms. There was, however, a correlation with the serology for the same monitoring point (both antinucleocapsid IgG and ELISpot negative or positive in 14/19 cases), with two subjects with negative serology but a positive ELISpot and three with a negative ELISpot but positive serology, i.e. a correlation of 73.7%. For anti-spike IgG, the correlation was only 10/19 (52.6%) ( Table 3) . COVID-19 is a major global healthcare challenge. The disease spectrum varies widely, ranging from asymptomatic or with only mild symptoms to severe disease and death. Understanding the temporal profile by which circulating antibody classes are produced following SARS-CoV-2 infection is essential for the interpretation and clinical application of serological test results. After symptom onset or a positive RT-PCR, all included HCWs were tested positive for SARS-CoV-2 IgG within 21 to 28 days regardless of their age, gender, risk factors, or symptoms but there were variations between individuals. In our hospital, the prevalence of serological positivity among healthcare workers was 6.8%. Despite our relatively young population, with a median age of 47 years, we observed an association between longer anti-nucleocapsid IgG half-lives and increasing age. This may be related to boosting of cross-reactivity with other human coronaviruses [18] . Although IgM immunoglobulins are expected to be the first class detected following infection by SARS-CoV-2, as supported by several studies [14, 19] , other studies have paradoxically demonstrated IgG responses preceding the IgM response [20, 21] . This surprising discrepancy is likely related to cross-reactivity with pre-existing immunity to human coronaviruses. A/pauci-symptomatic and symptomatic patients produced specific SARS-CoV-2 antibodies during the acute phase of the disease, but it is difficult to conclude whether there is a correlation between SARS-CoV-2 IgG kinetics and COVID-19 clinical symptoms, as there was an imbalance between asymptomatic and symptomatic cases. Other studies reported that asymptomatic individuals become seronegative in the early convalescent phase faster than symptomatic individuals, presumably due to a weaker immune response to SARS-CoV-2 infection in the asymptomatic population [14] . We also showed that SARS-CoV-2 anti-nucleocapsid IgG indexes start to decrease early (1 month after infection), and their duration is significantly correlated with the initial antibody titers. This motivated the second cohort study with the longitudinal follow-up of HCWs previously infected with SARS-CoV-2. Indeed, individuals with low titers of SARS-CoV-2 IgG may be more likely to become seronegative as early as 3 months for some of them. days after symptom onset [24, 25] , showing the trend and the rapid increase of IgG titers during the acute phase of COVID-19. However, a recent study that analyzed the long-term kinetics of neutralizing anti-SARS-CoV-2 antibodies suggested that anti-spike IgG are durable [26] , with only a modest decline in titers months after symptom onset, and almost all individuals appeared to remain positive for anti-spike IgG 5 to 7 months after COVID-19 infection [27, 28] . However, the progressive decrease in titers of anti-spike antibodies raises the question of the need for future booster vaccinations. Conversely, other studies indicated that although anti-spike IgG can last for more than 6 months after SARS-CoV-2 infection, there is still a significant reduction in antibody titers [29] , which possibly predicts the progressive loss of protective antibody response within several months after SARS-CoV-2 infection [30] . We observed a progressive decline of both anti-nucleocapsid and anti-spike IgG titers in our study. However, a significant reduction of IgG titers only concerned anti-nucleocapsid IgG until negativation according to the interpretation criteria and even undetectable in some cases, whereas anti-spike IgG titers consistently remained above the positivity threshold. The cellular response evaluated in 18 patients only showed 42% positivity at Month 8. This result shows that the long-term immune memory to SARS-CoV-2 of a/pauci-symptomatic patients is weak, as previously described [31] . It also suggests that protection against re-infection is not complete in this context, in favor of appropriate vaccination even in this population. However, patients with symptomatic COVID-19 in the first wave of infections are at significantly lower risk of positive PCR test later on [4, 32] . In our study, two cases of recurrence (new SARS-CoV-2 RT-PCR positivity) were diagnosed during the investigation of a cluster suggesting transient carriage rather than reinfection due to the absence of symptoms. In our study, as in the previous one, a significant proportion of caregivers (32.4%) reported persistence of symptoms falling within the definition of post-acute COVID-19 syndrome [33, 34] . No correlation between the kinetics of anti-spike or anti-nucleocapsid IgG could be demonstrated. A systematic study of sequelae after recovery from acute COVID-19 is required to develop an evidence-based multidisciplinary team approach to manage these patients and to inform research priorities. Our study had several limitations. First, we did not study the seroconversion date postsymptom onset or after a positive RT-PCR. Second, we did not test the neutralizing activities of the anti-SARS-CoV-2 nucleocapsid or spike antibodies and do not know whether or not their presence confers protective immunity. Finally, we could not analyze the association between immune response and clinical course due to the imbalance between symptomatic and asymptomatic cases. This study confirms literature data on the early decrease in anti-N and slower decrease in anti-S antibodies with persistence of antibodies at a certain level. Our study results confirm that infection should be followed by vaccination because of antibody decrease. The trial obtained approval from the independent Ethics Committee "Sud Méditérrannée I" on 05/05/2020 (2020-A01837-32) and was conducted according to Good Clinical Practices and the Declaration of Helsinki, as last amended. The study was sponsored by the Groupe Hospitalier Paris Saint-Joseph Characteristics of SARS-CoV-2 and COVID-19 Epidemiology of and Risk Factors for Coronavirus Infection in Health Care Workers: A Living Rapid Review Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers Antibody tests for identification of current and past infection with SARS-CoV-2 Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison SARS-CoV-2-IgG response is different in COVID-19 outpatients and asymptomatic contact persons Antibody Detection and Dynamic Characteristics in Patients With Coronavirus Disease Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19) Postacute COVID-19 syndrome SARS-CoV-2 responsive T cell numbers are associated with protection from COVID-19: A prospective cohort study in keyworkers. Infectious Diseases (except HIV/AIDS) Covid-19: What do we know about "long covid Cross-reactivity towards SARS-CoV-2: the potential role of low-pathogenic human coronaviruses Comparison of immunoglobulin G subclass profiles induced by measles virus in vaccinated and naturally infected individuals Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice Dynamics of anti-SARS-Cov-2 IgM and IgG antibodies among COVID-19 patients Prior COVID-19 significantly reduces the risk of subsequent infection, but reinfections are seen after eight months Dynamic anti-spike protein antibody profiles in COVID-19 patients Antibody responses to SARS-CoV-2 in patients with COVID-19 Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers Robust neutralizing antibodies to SARS-CoV-2 infection persist for months Viral and Antibody Kinetics of COVID-19 Patients with Different Disease Severities in Acute and Convalescent Phases: A 6-Month Follow-Up Study Three-month Follow-up Study of Survivors of Coronavirus Disease 2019 after Discharge Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections Prior SARS-CoV-2 infection is associated with protection against symptomatic reinfection Sixty-Day Outcomes Among Patients Hospitalized With COVID-19 Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort The authors would like to thank all colleagues who agreed to participate in the study.